StockNews.com Initiates Coverage on Bio-Path (NASDAQ:BPTH)

StockNews.com started coverage on shares of Bio-Path (NASDAQ:BPTH) in a report issued on Friday morning. The brokerage issued a sell rating on the stock.

Bio-Path Stock Performance

BPTH opened at $0.63 on Friday. The stock’s fifty day moving average is $0.89 and its two-hundred day moving average is $0.98. Bio-Path has a 52 week low of $0.59 and a 52 week high of $9.83.

Bio-Path Company Profile

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.